Search clinical trials for: Gemcitabine/Cisplatin /S-1

Total 1608 results

Sun Yat-sen University
The First Affiliated Hospital of Guangzhou Medical University; Affiliated Cancer... and other collaborators

Not yet recruiting

Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Instituto do Cancer do Estado de São Paulo

Unknown

Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. (CIRCE)

Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t

Brazil
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Bladder Cancer

United States, Canada
Gao Yajie

Unknown

Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy (LCKY2015-21(x))

Carcinoma, Non-Small-Cell Lung

China
Jonsson Comprehensive Cancer Center
Eli Lilly and Company

Terminated

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage IV HPV-Mediated (p16-Positive)... and other conditions

United States
Spanish Oncology Genito-Urinary Group
Roche Pharma AG

Completed

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA)

Locally Advanced or Metastatic Urothelial Carcinoma

Spain
Brown University
Lifespan

Terminated

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

Bladder Cancer | Invasive Bladder Cancer

United States
Incyte Corporation

Completed

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Breast Cancer | Multiple Myeloma | Gastric Cancer | Lung Cancer | Solid Tumor | Cholangiocarcinoma | Endometrial Cancer | Urothelial Cancer | Myeloproliferative Neoplasms | UC | MPN

United States, Denmark
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Completed

Sorafenib Plus S-1 in Advanced Solid Tumors

Advanced Solid Tumors

Taiwan
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Fondazione C.N.R./Regione Toscana "G. Monasterio...

Unknown

Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Bladder Cancer

Italy
Eli Lilly and Company

Completed

Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes

Non-Small Cell Lung Cancer

Poland
Eli Lilly and Company

Completed

Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer

Carcinoma, Non Small Cell Lung

United States
Mingzhi Zhang
Shanxi Province Cancer Hospital; Wuhan University; Qingdao University; Wuhan Union... and other collaborators

Unknown

Treatment of Natural Killer/T Cell Lymphoma-I/II (CTTNKTL-I/II)

Nasal and Nasal-type NK/T-cell Lymphoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage III Uterine Corpus... and other conditions

United States
Guarionex J. Decastro
Sanofi

Active, not recruiting

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (CGC)

Urothelial Carcinoma of the Urinary Bladder

United States
University of Kentucky
Bayer

Terminated

Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

Bladder Cancer

United States
Fox Chase Cancer Center

Terminated

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Stage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder Cancer

United States
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
Lombardi Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Wuhan Union Hospital, China

Recruiting

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma

China
Hinova Pharmaceuticals Inc.

Recruiting

A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Metastatic Castration-resistant Prostate Cancer

China
GlaxoSmithKline
Walter Reed Army Institute of Research (WRAIR); The PATH Malaria Vaccine Initiative...

Completed

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell Carcinoma | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma and other conditions

United States
The University of Hong Kong
London School of Hygiene and Tropical Medicine; Nagasaki University

Enrolling by invitation

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18

Healthy

United Kingdom
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
AIO-Studien-gGmbH
AstraZeneca

Completed

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients (IMMUCHEC)

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Gall Bladder Carcinoma | Gallbladder Carcinoma Non-Resectable

Germany
NuCana plc

Terminated

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Canada, United States, Spain, Hungary, Korea, Republic of, United Kingdom, Czechia, Germany, Russian Federation, Australia, France, Taiwan, Ukraine, Italy, Turkey
IRCCS San Raffaele

Recruiting

PAXG Out in the Country (OINC)

Pancreatic Ductal Adenocarcinoma

Italy
ANRS, Emerging Infectious Diseases
INSERM SC10-US19

Recruiting

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (SYNACTHIV)

HIV-1-infection, Subtype b

Belgium, France
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

Hepatic Complication

United States
Shi Ming

Recruiting

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Bladder Cancer

China
AHS Cancer Control Alberta
Celgene

Active, not recruiting

A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC)

Unresectable Biliary Tract Cancer

Canada
Clovis Oncology, Inc.

Terminated

A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

Lung Cancer | Solid Tumor | Non-small-cell Lung Cancer

United States, United Kingdom
Herbert Irving Comprehensive Cancer Center

Completed

Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Lung Cancer
National Cancer Institute (NCI)

Completed

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach

Gastric Cancer | Pancreatic Cancer

United States
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
CHA University
Dong-A Pharmaceutical

Recruiting

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of
Forma Therapeutics, Inc.

Completed

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) | Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) | Cohort 3a and 3b: Chondrosarcoma | Cohort 4a and 4b: Intrahepatic... and other conditions

United States, Korea, Republic of, Australia, United Kingdom, Spain, France
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Universitätsklinikum Köln, Germany; Universitätsklinikum Düsseldorf...

Not yet recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma | Unresectable Perihilar or Ductal CCA

Germany
Seoul National University Hospital

Active, not recruiting

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Biliary Tract Neoplasms

Korea, Republic of
Memorial Sloan Kettering Cancer Center
University of Chicago; Genentech, Inc.; Ohio State University; Targos

Active, not recruiting

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Urothelial Carcinoma | Locally Advanced | Unresectable

United States
IRCCS San Raffaele

Completed

Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer (PACT-9)

Pancreatic Cancer

Italy
University Hospital, Antwerp
Eli Lilly and Company; Universiteit Antwerpen

Completed

Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC (CHER@NOS)

Non-Small-Cell-Lung Cancer

Belgium

Search clinical trials for: Gemcitabine/Cisplatin /S-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations